Co-formulated favezelimab plus pembrolizumab versus standard-of-care in previously treated, PD-L1-positive metastatic colorectal cancer: The phase 3, randomized KEYFORM-007 study. Authors: Neil Howard ...

On Friday, Guggenheim Securities adjusted its outlook on Merck (NS: PROR) & Co Inc (NYSE:MRK) shares, reducing the pharmaceutical giant's price target from $130.00 to $122.00 while reaffirming a ...

Merck, known as MSD outside of the United States and Canada, announced the discontinuation of the clinical development programmes for vibostolimab, an anti-TIGIT antibody, and favezelimab, an anti-LAG ...

Merck, known as MSD outside of the United States and Canada, announced the discontinuation of the clinical development programmes for vibostolimab, an anti-TIGIT antibody, and favezelimab, an anti-LAG ...

Favezelimab is being evaluated as an investigational fixed-dose combination with pembrolizumab in the KEYFORM program. Merck is discontinuing the Phase 3 KeyVibe-003 and KeyVibe-007 trials, which ...

Merck, known as MSD outside of the United States and Canada, today announced the discontinuation of the clinical development programs for vibostolimab, an anti-TIGIT antibody, and favezelimab, an ...

The New Jersey-based drugmaker is ending development of anti-TIGIT antibody vibostolimab and anti-LAG-3 antibody favezelimab, according to a Dec. 16 release shared after market close.

Merck (MRK) announced the discontinuation of the clinical development programs for vibostolimab, an anti-TIGIT antibody, and favezelimab, an anti-LAG-3 antibody. Vibostolimab is being evaluated as ...

Dec 16 (Reuters) - Merck (MRK.N), opens new tab said on Monday it has discontinued the development of two experimental cancer drugs after their failure in several trials. The pharmaceutical giant ...

Researchers assigned half of the patients to a fixed-dose combination of 800 mg favezelimab (MK-4280, Merck) — an investigational anti-lymphocyte activation gene-3 antibody that aims to restore ...